Genetic Link Found Between Immune System and Lymphoma
|
By LabMedica International staff writers Posted on 12 Dec 2017 |
|
Image: A diagram of the Kompetitive Allele Specific Polymerase Chain Reaction (PCR KASP) method (Photo courtesy of J.P. Livingstone).
Classical Hodgkin lymphoma (cHL) is a lymphoid malignancy of germinal center (GC) B-cell origin, which is characterized by Hodgkin and Reed–Sternberg (HRS) cells with a dominant background population of reactive inflammatory cells.
People who inherit genetic changes that alter the function of their immune system are at increased risk of developing Hodgkin lymphoma. Of the four major subtypes of cHL, nodular sclerosis Hodgkin lymphoma (NSHL) and mixed cellularity Hodgkin lymphoma (MCHL) account for 65% and 20% of cHL, respectively.
A large group of scientists collaborating with The Institute of Cancer Research (London, UK) analyzed genetic data from 5,314 cases of Hodgkin lymphoma and 16,749 controls, from four different European studies. They analyzed constitutional DNA from 1,717 cases, which were genotyped using the Illumina Oncoarray (Illumina Inc, San Diego, CA, USA). The fidelity of genome-wide association study (GWAS) imputation was assessed by the concordance between imputed and directly genotyped single nucleotide polymorphisms (SNP) in a subset of samples. Replication genotyping of UK samples was performed using Polymerase Chain Reaction Kompetitive Allele Specific (PCR KASP) chemistry.
The investigators identified six new single-letter changes in DNA that were linked to the development of Hodgkin lymphoma and five of these affect the way a type of white blood cell, called B cells, develop. The study also showed clear differences in genetic risk between two different subtypes of Hodgkin Lymphoma and NSHL and MCHL. For example, a single-letter change located in DNA near the gene LIM Domain Containing Preferred Translocation Partner In Lipoma (LPP) increased the risk of NSHL by 37%, but had little effect on the risk of developing MCHL.
Richard S. Houlston, FMedSci, FRS, a Professor of Molecular and Population Genetics and senior author of the study, said, “Hodgkin lymphoma is a cancer of immune cells called B cells, and our study links the risk of the disease to changes in the genes that control how B cells develop. Interestingly, we found that some of the genetic changes we have linked to Hodgkin lymphoma have previously been associated with the risk of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The new information could point towards new ways of diagnosing, treating, or even helping to prevent Hodgkin lymphoma.” The study was published on December 1, 2017, in the journal Nature Communications.
Related Links:
The Institute of Cancer Research
Illumina Oncoarray
People who inherit genetic changes that alter the function of their immune system are at increased risk of developing Hodgkin lymphoma. Of the four major subtypes of cHL, nodular sclerosis Hodgkin lymphoma (NSHL) and mixed cellularity Hodgkin lymphoma (MCHL) account for 65% and 20% of cHL, respectively.
A large group of scientists collaborating with The Institute of Cancer Research (London, UK) analyzed genetic data from 5,314 cases of Hodgkin lymphoma and 16,749 controls, from four different European studies. They analyzed constitutional DNA from 1,717 cases, which were genotyped using the Illumina Oncoarray (Illumina Inc, San Diego, CA, USA). The fidelity of genome-wide association study (GWAS) imputation was assessed by the concordance between imputed and directly genotyped single nucleotide polymorphisms (SNP) in a subset of samples. Replication genotyping of UK samples was performed using Polymerase Chain Reaction Kompetitive Allele Specific (PCR KASP) chemistry.
The investigators identified six new single-letter changes in DNA that were linked to the development of Hodgkin lymphoma and five of these affect the way a type of white blood cell, called B cells, develop. The study also showed clear differences in genetic risk between two different subtypes of Hodgkin Lymphoma and NSHL and MCHL. For example, a single-letter change located in DNA near the gene LIM Domain Containing Preferred Translocation Partner In Lipoma (LPP) increased the risk of NSHL by 37%, but had little effect on the risk of developing MCHL.
Richard S. Houlston, FMedSci, FRS, a Professor of Molecular and Population Genetics and senior author of the study, said, “Hodgkin lymphoma is a cancer of immune cells called B cells, and our study links the risk of the disease to changes in the genes that control how B cells develop. Interestingly, we found that some of the genetic changes we have linked to Hodgkin lymphoma have previously been associated with the risk of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The new information could point towards new ways of diagnosing, treating, or even helping to prevent Hodgkin lymphoma.” The study was published on December 1, 2017, in the journal Nature Communications.
Related Links:
The Institute of Cancer Research
Illumina Oncoarray
Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Latest Hematology News
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more
Hematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
Lower-respiratory tract infections (LRTIs) are a leading cause of illness and death worldwide, and pneumonia is the leading infectious cause of death in children under five, claiming the lives of over... Read more
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more
Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read more
Common Health Issues Can Influence New Blood Tests for Alzheimer’s Disease
Blood-based tests for Alzheimer’s disease are transforming diagnosis by offering a simpler alternative to spinal taps and brain imaging. However, many people evaluated at memory clinics also live with... Read more
Blood Test Formula Identifies Chronic Liver Disease Patients with Higher Cancer Risk
Chronic liver disease affects millions worldwide and can progress silently to hepatocellular carcinoma (HCC), one of the deadliest cancers globally. While surveillance guidelines exist for patients with... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
Industry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more
